James Rouse, president and CEO, has been elected a director of Arrhythmia Research Technology (Fitchburg, Massachusetts) for a three-year term. The company also reported the appointment of David Garrison as chief financial officer. Garrison recently joined the company as corporate controller after nine years as controller and CFO of H & R 1871, a privately held manufacturer of single-barrel shotguns.
Gerard Mahoudeau was named director, European business, of CryoCath Technologies (Montreal, Quebec), which provides cryotherapy products to treat cardiovascular disease. Mahoudeau was named to head the company's 15-person sales and clinical support team in Europe. Most recently, Mahoudeau was vice president, Cardiac Surgery Europe, at Medtronic, where he was responsible for European operations as well as those in Africa and the Middle East.
Steve Hanni has been named chief financial officer of Emergency Filtration Products (EFP; Henderson, Nevada). Hanni has worked closely with EFP for the past five years as outside auditor and most recently as a financial and accounting consultant. EFP is an air filtration products manufacturer. Initial products developed for the medical market are the Vapor Isolation Valve; RespAide, a CPR mask used for resuscitation of respiratory/cardiac arrest cases; an AED prep kit; and the 2H Breathing Circuit Filter.
Robert Horn has joined Endovasc (Montgomery, Texas) as managing director-finance. He formerly was CFO of Surgicare. Endovasc has two cardiovascular drugs in final Phase III human trials.
Dr. David Higgins has been named vice president for business development for Oxford BioMedica (San Diego, California/Oxford, England). He will join Oxford BioMedica's San Diego subsidiary to head business development in the U.S. Higgins previously worked in project management and business development for Invitrogen, Chiron and Idun Pharmaceuticals. Oxford BioMedica was spun off from Oxford University and specializes in gene-based products and technology in the areas of cancer, neurological disease, cardiovascular disease and blood disorders.
Gregory Cash has been named president and chief operating officer of Vasomedical (Westbury, New York), manufacturer of enhanced external counterpulsation (EECP) systems used in the treatment of angina, cardiogenic shock, acute myocardial infarction and congestive heart failure. Cash most recently served as corporate vice president of Datascope and president of its wholly owned subsidiary, Intervascular Inc., prior to which he was with U.S. Surgical, Boston Scientific and Medtronic.